These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8271141

  • 1. Promising new treatment for type I tyrosinemia.
    Heubi JE.
    J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):340-1. PubMed ID: 8271141
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. NTBC as palliative treatment in chronic tyrosinaemia type I.
    Ros J, Vilaseca MA, Lambruschini N, Mas A, Lindstedt S, Holme E.
    J Inherit Metab Dis; 1999 Jun; 22(5):665-6. PubMed ID: 10399099
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
    Bird S, Miller NJ, Collins JE, Rice-Evans CA.
    J Inherit Metab Dis; 1995 Jun; 18(2):123-6. PubMed ID: 7564225
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
    Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B.
    Lancet; 1992 Oct 03; 340(8823):813-7. PubMed ID: 1383656
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Mitchell GA.
    Hum Exp Toxicol; 1996 Feb 03; 15(2):179-81. PubMed ID: 8645506
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Late onset type I tyrosinemia].
    Klujber V, Sallai A, Kálmánchey R, Szönyi L, Hosszú E.
    Orv Hetil; 1997 Jul 13; 138(28):1805-8. PubMed ID: 9280876
    [Abstract] [Full Text] [Related]

  • 14. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.
    Gibbs TC, Payan J, Brett EM, Lindstedt S, Holme E, Clayton PT.
    J Neurol Neurosurg Psychiatry; 1993 Oct 13; 56(10):1129-32. PubMed ID: 8410015
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
    Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL.
    J Inherit Metab Dis; 1998 Aug 13; 21(5):498-506. PubMed ID: 9728330
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis and management of tyrosinemia type I.
    Holme E, Lindstedt S.
    Curr Opin Pediatr; 1995 Dec 13; 7(6):726-32. PubMed ID: 8776026
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
    Grompe M, Overturf K, al-Dhalimy M, Finegold M.
    J Inherit Metab Dis; 1998 Aug 13; 21(5):518-31. PubMed ID: 9728332
    [Abstract] [Full Text] [Related]

  • 20. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S, Baumann U.
    Expert Opin Pharmacother; 2008 May 13; 9(7):1229-36. PubMed ID: 18422479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.